Jaramillo, S., Krisam, J., Le Cornet, L., Kratzmann, M., Baumann, L., Eissymont, O., Crysandt, M., Görner, M., Kayser, S., Krause, S., Schliemann, C., Gaska, T., Kaufmann, M., Chemnitz, J., Schaich, M., Hoellein, A., Platzbecker, U., Kieser, M., Müller-Tidow, C. and Schlenk, R. F. (2024) “Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia”, Haematologica. Pavia, Italy, 109(6), pp. 1973-1976. doi: 10.3324/haematol.2023.284346.